USPTO serial 97433023
TILRAY MEDICAL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- KEELEY, ALISON REBECCA
- Law office
- TMO LAW OFFICE 113
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with TILRAY MEDICAL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
New York, NY, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
PETER SLOANE
PETER SLOANE LEASON ELLIS LLPOne North Lexington Ave., Suite 1200White Plains, NY 10601United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Cannabis related products, namely, medicated oils, salves, tinctures, tablets and capsules, each containing cannabis for medicinal purposes for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; oils, salves, tinctures, tablets and capsules each containing resins and oils derived from cannabis for medicinal purposes for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; nutraceuticals for medicinal purposes for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; nutraceuticals for medicinal purposes containing cannabis for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; nutraceuticals for medicinal purposes containing derivatives of cannabis, namely, resins and oils for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; medicated topical skin creams, bar and liquid soaps, bath additives, bath herbs, bath oils, body creams, body oils, face and body lotions, face and body milk, face lotion, and skin care preparations each containing derivatives of cannabis, for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; personal sexual lubricants; transdermal patches containing cannabis for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; oral sprays containing cannabis for medicinal use for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; cannabis for medicinal purposes, namely, gummy vitamins for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; cannabis related product, namely, oils for medicinal use for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; oils derived from cannabis for medicinal use for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; none of the foregoing containing cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of more than 0.3 percent on a dry weight basis | ACTIVE | — |
| 031 | Live cannabis plants; Cannabis seeds for agricultural purposes; derived solely from hemp plants containing no more than .3 percent delta-9 tetrahydrocannabinol (THC) concentration by dry weight basis | ACTIVE | — |
| 041 | Providing entertainment information in the field of cannabis culture via a website; providing news via a website in the nature of current event reporting in the field of cannabis and cannabis culture; providing educational information in the field of cannabis-themed cultural events and festivals via a website | ACTIVE | — |
| 042 | Research services, namely, medical, scientific, foods, cosmetic, product, and agricultural research in the area of cannabis, cannabis related products, derivatives of cannabis, and natural health products containing cannabis; none of the foregoing services featuring or providing cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of more than 0.3 percent on a dry weight basis | ACTIVE | — |
| 044 | Providing the breeding, growing, cultivation, and harvesting of cannabis for others; production of cannabis, namely, cultivation of cannabis plants, for others; none of the foregoing services featuring or providing cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of more than 0.3 percent on a dry weight basis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Tilray Brands, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 031
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TILRAY MEDICAL
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 21, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 21, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 5, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 8, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 8, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 8, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 4, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 2, 2025 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Oct 2, 2025 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Oct 2, 2025 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 5, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 5, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 5, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 5, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 5, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 4, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 4, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 4, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 4, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 4, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 3, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 16, 2025 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 16, 2025 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 16, 2025 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 18, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 18, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 18, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 17, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 17, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 17, 2024 | ALIE | ASSIGNED TO LIE | — |
| Jan 30, 2024 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 16, 2023 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 16, 2023 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 16, 2023 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| May 19, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 19, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 19, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 25, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 25, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 31, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 24, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 4, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 3, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 31, 2022 | NWAP | NEW APPLICATION ENTERED | — |